Pretreatment D‐dimer levels have been reported to predict survival in several types of malignancies in human patients. The objective of this study was to evaluate the prognostic value of pretreatment D‐dimer level in dogs with intermediate to high‐grade non‐Hodgkin lymphoma (NHL). In a prospective, randomized, double‐blind study of F14512 vs etoposide phosphate, we assessed the prognostic value of pretreatment plasma D‐dimer level in 48 client‐owned dogs diagnosed with intermediate to high‐grade NHL. The correlation between pretreatment plasma D‐dimer level and various clinical features, progression‐free survival (PFS) and overall survival (OS) was analysed. The median value of pretreatment plasma D‐dimer level was 0.4 μg/mL (range: 0.1‐14.3 μg/mL). High pretreatment plasma D‐dimer level (>0.5 μg/mL) was detected in 44% (21/48) of dogs. High D‐dimer levels were not correlated with naive vs relapsed lymphoma, clinical stage, substage, immunophenotype or treatment group. D‐dimer levels >0.5 μg/mL were significantly associated with inferior median PFS (54 vs 104 days, P = .011) and OS (93 vs 169 days, P = .003). In the multivariate analysis, high D‐dimer levels remained an independent predictor for worse PFS (HR: 3.21, 95% CI: 1.57‐6.56, P = .001) and OS (HR: 3.87, 95% CI: 1.88‐7.98; P < .001). This study suggests that pretreatment plasma D‐dimer level can serve as a predictor of prognosis in dogs with intermediate to high‐grade NHL. Further studies are warranted to confirm these findings.

中文翻译：

---

中度至高度非霍奇金淋巴瘤犬治疗前血浆 D-二聚体水平的预后价值

据报道，治疗前 D-二聚体水平可预测人类患者几种类型恶性肿瘤的存活率。本研究的目的是评估治疗前 D-二聚体水平对中度至高度非霍奇金淋巴瘤 (NHL) 犬的预后价值。在一项 F14512 与磷酸依托泊苷的前瞻性、随机、双盲研究中，我们评估了 48 只诊断为中度至高度 NHL 的客户自有狗的治疗前血浆 D-二聚体水平的预后价值。分析了治疗前血浆 D-二聚体水平与各种临床特征、无进展生存期（PFS）和总生存期（OS）之间的相关性。治疗前血浆 D-二聚体水平的中值为 0.4 μg/mL（范围：0.1-14.3 μg/mL）。在 44% (21/48) 的狗中检测到高预处理血浆 D-二聚体水平 (>0.5 μg/mL)。高 D-二聚体水平与初治与复发淋巴瘤、临床分期、亚期、免疫表型或治疗组无关。D-二聚体水平 >0.5 μg/mL 与较差的中位 PFS（54 天 vs 104 天，P = .011) 和 OS（93 天对 169 天，P = .003）。在多变量分析中，高 D-二聚体水平仍然是较差 PFS（HR：3.21，95% CI：1.57-6.56，P = .001）和 OS（HR：3.87，95% CI：1.88-7.98；P  < .001)。该研究表明，治疗前血浆 D-二聚体水平可作为中度至高度 NHL 犬预后的预测指标。需要进一步的研究来证实这些发现。